Home | Articles
Published on:October 2020
Indian Journal of Pharmaceutical Education and Research, 2020; 54(3s):s390-s399
Review Article | doi:10.5530/ijper.54.3s.137

Insights on SARS-CoV-2: Emerging Outbreaks of Viral Infections and the Need for Heightening the Antiviral Research


Authors and affiliation (s):

Ramalingam Peraman1,*, Raghuveer Varma Pemmadi1, Muthukumaran Peraman2, Sathish Kumar Sure1

1RERDS-Centre for Pharmaceutical Research, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, Anantapur, Andhra Pradesh, INDIA.

2Department of Biotechnology, Kumaraguru College of Technology, Coimbatore, Tamil Nadu, INDIA.

Abstract:

Background: Today, about 47 life threatening viruses have been notified for their outbreak potentials including SAR-CoV-2. The proximal origin of SARS-CoV-2 and its affinity to human ACE2 receptors ended in COVID-19 disease pandemic. The genome of SARS-CoV-2 is quite complex and unclear, thus the progress on new antiviral drugs and vaccine discovery is hampered. Worldwide, Indian horizon has emerged as potential source for supply of drugs like hydroxychloroquine, remdesvir, ritonavir lopinavir, etc., to several countries. However, the research initiatives undertaken by Indian industries to fight against COVID-19 are relatively lower than the research attempts of developed countries. Furthermore, Indian industry’s collaboration with scientists of research institutes or universities is also very limited. Therefore, the need for enhancing antiviral research activities in India is highly recommended to combat COVID-19 like pandemic, if arise in future as well. Hypothesis: Being Indian pharma market as one of the top five leading pharma marketer of this globe, the COVID-19 pandemic lessoned us to realize the need for improving the antiviral research among pharmaceutical industries of Indian horizon. It is needed for the hour as measure to sustain the pharma market credibility at globe. Results and Conclusion: In this raising era of viral epidemics, it is imperative that Indian pharmaceutical industries should initiate antiviral research through collaborative approach between pharmaceutical industry and scientists across the globe including researchers from academia and non-profit research organization. Thus, this attempt will definitely improve the antiviral and other drug discovery research initiatives among Indian pharmaceutical industries and will save millions of life from viral pandemics like COVID-19 in near future.

Key words: Emerging viruses, Antiviral, COVID-19, Pharma industries, Indian Horizon, SARS-CoV-2 genome.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).

 

Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs